ACET

SEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 119,745

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.93 to $13.62, inclusive.

F5 · ownership.nature: Represents 119,745 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 143,728

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.88 to $12.87, inclusive.

F4 · ownership.nature: Represents 143,728 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 124,245

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.93 to $13.62, inclusive.

F5 · ownership.nature: Represents 119,745 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 149,128

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.88 to $12.87, inclusive.

F4 · ownership.nature: Represents 143,728 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 127,229

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive.

F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 152,710

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive.

F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 129,318

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive.

F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 155,218

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive.

F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 127,229

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive.

F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 152,710

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive.

F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 129,318

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive.

F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 155,218

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive.

F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee.

SEC source: 0000899243-21-009877 · doc4.xml · derivative · entry 2

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,828

Underlying: Common Stock · 28,828 shares

Expires 2031-03-01

F3 · derivative.exercise_date: 33% of the shares shall become exercisable on March 2, 2022, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0000899243-21-012024 · doc4a.xml · derivative · entry 2

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,828

Underlying: Common Stock · 28,828 shares

Expires 2031-03-01

F3 · derivative.exercise_date: 33% of the shares shall become exercisable on March 2, 2022, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0000899243-21-007032 · doc4.xml · derivative · entry 1

ABBOT STEWART · CIK 0001655597 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,900

Underlying: Common Stock · 106,900 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-007031 · doc4.xml · derivative · entry 1

Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,100

Underlying: Common Stock · 41,100 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-007028 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,200

Underlying: Common Stock · 28,200 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of the Vesting Start Date and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company.

SEC source: 0000899243-21-007024 · doc4.xml · derivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,400

Underlying: Common Stock · 30,400 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of the Vesting Start Date and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company.

SEC source: 0000899243-21-007023 · doc4.xml · derivative · entry 1

Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,200

Underlying: Common Stock · 11,200 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-007022 · doc4.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,600

Underlying: Common Stock · 421,600 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-007018 · doc4.xml · derivative · entry 1

Galimi Francesco · CIK 0001823996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000947871-21-000240 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 396,657

F2 · shares: These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F5 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.

F6 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon ("Gordon") and Erez Chimovits ("Chimovits") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-000240 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,243,259

F2 · shares: These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F6 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon ("Gordon") and Erez Chimovits ("Chimovits") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-000241 · ownership.xml · nonDerivative · entry 4

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 396,657

F2 · shares: These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F5 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of the Reporting Person, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.

F6 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-000241 · ownership.xml · nonDerivative · entry 2

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,243,259

F2 · shares: These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F6 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-000242 · ownership.xml · nonDerivative · entry 4

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 396,657

F2 · shares: These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F5 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of the Reporting Person, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.

F6 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-000242 · ownership.xml · nonDerivative · entry 2

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,243,259

F2 · shares: These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F6 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 9

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F10 · shares: Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F10 · price: Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F10 · ownership.nature: Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 8

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F9 · shares: Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F9 · price: Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F9 · ownership.nature: Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 7

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F8 · shares: Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F8 · price: Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F8 · ownership.nature: Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 6

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F7 · shares: Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F7 · price: Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F7 · ownership.nature: Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

SEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 5

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F6 · shares: Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F6 · price: Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

F6 · ownership.direct: Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4.

SEC source: 0000899243-21-002194 · doc4.xml · derivative · entry 1

Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-002192 · doc4.xml · derivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of the Vesting Start Date and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company.

SEC source: 0000899243-21-002193 · doc4.xml · derivative · entry 1

Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-002191 · doc4.xml · derivative · entry 1

Galimi Francesco · CIK 0001823996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-002190 · doc4.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-002188 · doc4.xml · derivative · entry 1

ABBOT STEWART · CIK 0001655597 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

SEC source: 0000899243-21-002189 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of the Vesting Start Date and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company.

SEC source: 0000899243-20-032694 · doc4.xml · derivative · entry 1

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,828

Underlying: Common Stock · 28,828 shares

Expires 2030-11-30

F1 · derivative.exercise_date: 33% of the shares shall become exercisable on December 1, 2021, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0000899243-20-029720 · doc4.xml · derivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,605

Underlying: Common Stock · 166,605 shares

Expires 2030-10-26

F1 · derivative.exercise_date: 25% of the shares of common stock subject to the option shall vest on October 27, 2021, and 1/36th of the remaining unvested shares subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the vesting commencement date thereafter.

SEC source: 0000899243-20-029358 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,499

F1 · shares: The Reporting Person is disposing of 8,649 restricted stock units as a result of a revised tax rate for such restricted stock units.

SEC source: 0000899243-21-012680 · doc4.xml · nonDerivative · entry 2

Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,931

F3 · shares: The Reporting Person is disposing of 4,957 restricted stock units as a result of a revised tax rate for such restricted stock units

SEC source: 0000899243-21-014397 · doc4a.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,070

F1 · shares: The Reporting Person is disposing of 8,649 restricted stock units as a result of a revised tax rate for such restricted stock units.

SEC source: 0000947871-20-000738 · ownership.xml · derivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-17

F10 · derivative.exercise_date: This option is held by Chimovits. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Chimovits remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, Chimovits is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II.

F10 · ownership.nature: This option is held by Chimovits. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Chimovits remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, Chimovits is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II.

SEC source: 0000947871-20-000738 · ownership.xml · derivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-17

F9 · derivative.exercise_date: This option is held by Gordon. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Gordon remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, Gordon is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefits are provided to OPI V and OPI VI.

F9 · ownership.nature: This option is held by Gordon. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Gordon remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, Gordon is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefits are provided to OPI V and OPI VI.

SEC source: 0000899243-20-025655 · doc4.xml · derivative · entry 1

DUBIN STEVE · CIK 0001265123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F1 · derivative.exercise_date: This option shall vest as follows: 1/36th of the shares shall vest on each of the next thirty-six (36) monthly anniversaries of the Vesting Commencement Date.

SEC source: 0000899243-20-025654 · doc4.xml · derivative · entry 2

Schindel Yair Chaim · CIK 0001823758 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F3 · derivative.exercise_date: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the vesting commencement date, provided that the reporting person remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025653 · doc4.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F8 · derivative.exercise_date: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the [vesting commencement date], provided that the reporting person remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025652 · doc4.xml · derivative · entry 1

Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,027

Underlying: Common Stock · 193,027 shares

Expires 2030-09-16

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries.